You are now leaving arenapharm.com and being directed to a site not maintained by Arena. Arena is not responsible for content or privacy policies on other sites.
Cancel Ok

APD418

APD418

APD418 is a potentially first-in-class, investigational, β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope for decompensated heart failure. APD418 is a selective antagonist designed to improve cardiac contractility with minimal effect on heart rate and blood pressure. Inhibition of β3-AdrR–mediated myofilament repression may provide a cardiomyocyte-specific target to enhance cardiac contractile performance. Arena discovered and developed this investigational drug internally.

Clinical Trial
ACUTE HEART FAILURE
Phase 2
APD418 is an investigational drug and is not currently approved for use by any health authority.
Retained Rights: Worldwide.